Reversible agranulocytosis associated with oral terbinafine in a pediatric patient.
We report a case of terbinafine-induced agranulocytosis in a pediatric patient. This effect was noted 4 weeks after starting terbinafine and resolved within 1 week without the institution of therapy with granulocyte colony-stimulating factor, a course similar to reports in adults. With the incidence of severe side effects still unclear in children, this case argues for continued blood surveillance during courses of terbinafine and for the confirmation of infection before initiation of the drug.
Aguilar
C
C
Beaufort Naval Hospital Department of Pediatrics, Beaufort, Wisconsin, USA.
Mueller
K K
KK
D000284:Administration, Oral; D000293:Adolescent; D000380:Agranulocytosis / Q000139:chemically induced* / Q000473:pathology; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009281:Naphthalenes / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D014009:Onychomycosis / Q000188:drug therapy; D000077291:Terbinafine; D014008:Tinea Pedis / Q000188:drug therapy
D000935:Antifungal Agents; D009281:Naphthalenes; D000077291:Terbinafine